INDUS PHARMACEUTICALS
Live / Registered — Registered and renewed (as of 03 Oct 2019)
What this means for you
Registered since 25 Aug 2009. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 25 Aug 2019).
Record
- Serial number
- 78596173
- Registration number
- 3674488
- Mark type
- Stylized text
- Filed
- 28 Mar 2005
- Published for opposition
- 21 Mar 2006
- Registered
- 25 Aug 2009
- Next maintenance due
- 25 Aug 2019
- Attorney of record
- H. Straat Tenney
Goods and services
- Class 042 — Scientific and technological services: pharmaceutical drug development services of pharmaceutical products intended for the treatment of infectious diseases, namely, bacterial, fungal, parasitic and viral infections; pharmaceutical drug development services of pharmaceutical products intended for the treatment of neoplastic disorders, namely, hematologic cancer disorders and solid tumors; pharmaceutical drug development services of pharmaceutical products intended for the treatment of autoimmune disorders, namely, diabetes, arthritis, psoriasis, bone marrow and organ transplantation and immunosuppression; pharmaceutical drug development services of pharmaceutical products intended for the treatment of metabolic disorders, namely, obesity and atherosclerosis; pharmaceutical drug development services of pharmaceutical products intended for the treatment of cardiovascular disorders, namely, hypertension, congestive heart failure, myocardial infarction, angina and vascular diseases; pharmaceutical drug development services of pharmaceutical products intended for the treatment of renal disorders, namely, acute and chronic renal failure and urinary disorders affecting renal conservation of water; pharmaceutical drug development services of pharmaceutical products intended for the treatment of central nervous system disorders, namely, analgesia, anesthesia, hypnotics, sedatives, anxiety, psychosis, depression, mania, epilepsies, migraine, neurodegeneration, and drug addiction; pharmaceutical drug development services of pharmaceutical products intended for the treatment of inflammatory disorders, namely, asthma, gout, inflammatory bowel disease, and rheumatoid arthritis; pharmaceutical drug development services of pharmaceutical products intended for the treatment of gastrointestinal disorders, namely, ulcers, emesis, diarrhea, and irritable bowel syndrome; pharmaceutical drug development services of pharmaceutical products intended for the treatment of hormonal disorders affecting the thyroid, estrogens, progestins, androgens, glucocorticoids, insulin and glucose regulation; pharmaceutical drug development services of pharmaceutical products intended for the treatment of calcification and bone turnover; and pharmaceutical drug development services of pharmaceutical products intended for the treatment of dermatological and opthalmological disorders
Owner
- IndUS Pharmaceuticals, Inc., Andover, MA, US
- IndUS Pharmaceuticals, Inc., Andover, MA, US
- IndUS Pharmaceuticals, Inc., Andover, MA, US
Prosecution history
- 03 Oct 2019 — NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
- 03 Oct 2019 — REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
- 03 Oct 2019 — REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
- 03 Oct 2019 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 23 Aug 2019 — TEAS SECTION 8 & 9 RECEIVED
- 25 Aug 2018 — COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
- 22 Jan 2016 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 25 Sept 2015 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 25 Sept 2015 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 25 Sept 2015 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 21 Aug 2015 — TEAS SECTION 8 & 15 RECEIVED
- 25 Aug 2009 — REGISTERED-PRINCIPAL REGISTER
- 21 Jul 2009 — LAW OFFICE REGISTRATION REVIEW COMPLETED
- 21 Jul 2009 — ASSIGNED TO LIE
- 13 Jul 2009 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED